Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Vertex Pharmaceuticals Inc

VRTX

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Last trade $533.69
Day change -$4.10 (-0.76%)
Day range $529.27 – $540.59
Volume 514,808
Market cap $136.35B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$136.35B
Price / earnings
34.29×
Price / book
6.52×
Price / sales
10.53×
EV / sales
10.49×
EV / EBITDA
29.41×

Profitability

Earnings per share
$15.68
Return on assets
12.15%
Return on equity
19.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.22×
Current ratio
2.34×
Quick ratio
1.89×
Cash ratio
1×

Cash flow

Price / cash flow
36.91×
Price / free cash flow
42.58×
Free cash flow
$3.2B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VRTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3.44B$3.33B$2.99B$3.19B$3.08B$2.96B$2.77B$2.91B
Cost of revenue$526.1M$489.2M$392.8M$466M$414.8M$407.5M$363M$423.4M
Gross profit$2.91B$2.84B$2.59B$2.72B$2.66B$2.56B$2.41B$2.49B
Selling, general and administrative$844.1M$582.2M$493.7M$487M$445.1M$424.6M$396.4M$377.6M
Research and development$1.36B$993.8M$961.6M$973.7M$1.03B$978.4M$979.7M$998.7M
Total operating expenses$2.2B$1.6B$1.46B$1.52B$1.48B$1.41B$1.78B$1.46B
Operating income$712.9M$1.25B$1.14B$1.21B$1.19B$1.15B$630.1M$1.03B
Interest expense-$36M$0$0-$3.3M-$3.3M$0$0-$2.8M
Income before taxes$783.4M$1.39B$1.25B$1.33B$1.3B$1.28B$730.4M$1.14B
Income taxes$129.8M$292M$221.5M$139.9M$215.9M$250.1M$84.1M$223.5M
Net income$653.6M$1.1B$1.03B$1.19B$1.08B$1.03B$646.3M$913M
Net income attributable to common shareholders$653.6M$1.1B$1.03B$1.19B$1.08B$1.03B$646.3M$913M
EBITDA$782.1M$1.32B$1.19B$1.32B$1.24B$1.21B$1.08B$1.16B
Basic earnings per share$2.58$4.34$4.06$4.70$4.24$4.02$2.52$3.55
Diluted earnings per share$2.56$4.31$4.02$4.65$4.20$3.99$2.49$3.63

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

The VanEck Biotech ETF (BBH) is a passively managed fund tracking the MVIS US Listed Biotech 25 Index with $521.91 million in assets and a low 0.35% expense ratio. The fund has delivered strong year-to-date returns of 31.47% but carries higher risk with a beta of 0.70 and concentrated exposure through its top 10 holdings representing 73.82% of assets. BBH holds a Zacks ETF Rank of 2 (Buy), though investors should consider alternatives like XBI and IBB.

The Motley Fool

Which Healthcare ETF Is the Better Buy: State Street’s Pharma Fund XPH or iShares’ Biotech Fund IBB?

The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.

The Motley Fool

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.

The Motley Fool

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.